872 views3 min read
Silo Pharma Produces SPU-21 Liposomes for Rheumatoid Arthritis Study
ENGLEWOOD CLIFFS, N.J., April 20, 2022 -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announces that it has produced its first batch of Liposomes for use in a preclinical study that will be conducted by Frontage Laboratories, a CRO (contract res... Read More...